Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1993 1
1996 1
1997 1
1999 1
2002 1
2003 1
2007 2
2008 4
2009 2
2010 4
2011 9
2012 13
2013 10
2014 11
2015 15
2016 20
2017 27
2018 25
2019 21
2020 26
2021 45
2022 43
2023 45
2024 57
2025 68
2026 46

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Results by year

Filters applied: . Clear all
Page 1
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Diseases and Injuries Collaborators. GBD 2021 Diseases and Injuries Collaborators. Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17. Lancet. 2024. PMID: 38642570 Free PMC article.
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
Brody JD, Jørgensen J, Belada D, Costello R, Trněný M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, André M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R. Brody JD, et al. Blood. 2025 Apr 10;145(15):1621-1631. doi: 10.1182/blood.2024026830. Blood. 2025. PMID: 39792928 Free PMC article. Clinical Trial.
Epcoritamab, a CD3 CD20 bispecific antibody approved for R/R DLBCL after 2 therapy lines, has shown promising safety and efficacy in various combinations. ...Epcoritamab plus GemOx yielded deep, durable responses and favorable long-term outcomes in ASCT-ineligible …
Epcoritamab, a CD3 CD20 bispecific antibody approved for R/R DLBCL after 2 therapy lines, has shown promising safety and effi …
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
Brooks TR, Zabor EC, Bedelu YB, Yang X, Karimi YH, Nedved AN, Wang Y, Dave N, Landsburg DJ, Baron K, Hu B, Trotier DC, Pophali PA, Miller J, Grover N, Reinert C, Major A, Schwarz T, Patel K, Salafian K, Ayers E, Sundaram S, Brody JD, McKenna M, Ryu Tiger YK, Sears-Smith M, Ghosh N, Peterson C, Khan C, Bliven SP, Narkhede M, Gibson A, Kline J, Munoz J, Garza-Morales R, Ho CI, Smith SD, Niu A, Hernandez-Ilizaliturri F, Chinyengetere F, Dave S, Abdel-Razeq N, Moustafa MA, Caimi PF, Hill BT. Brooks TR, et al. Blood. 2025 Oct 30;146(18):2177-2188. doi: 10.1182/blood.2025029117. Blood. 2025. PMID: 40663785
Patients with R/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collected from 21 United States institutions. ...These results demonstrate the activity of BsAbs in R/R DLBCL, and underscore the imp …
Patients with R/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collect …
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.
Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Jurczak W, Do YR, Gasiorowski R, Lewis DJ, Kim TM, van der Poel M, Poon ML, Feldman T, Linton KM, Sureda A, Hutchings M, Dinh MH, Kilavuz N, Soong D, Mark T, Sacchi M, Phillips T, Lugtenburg PJ. Thieblemont C, et al. Leukemia. 2024 Dec;38(12):2653-2662. doi: 10.1038/s41375-024-02410-8. Epub 2024 Sep 25. Leukemia. 2024. PMID: 39322711 Free PMC article.
Primary results (median follow-up, 10.7 months) from the pivotal EPCORE( ) NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated deep, durable responses with epcoritamab, a CD3xCD20 bispecific antibody, when used as monotherapy. ...Th …
Primary results (median follow-up, 10.7 months) from the pivotal EPCORE( ) NHL-1 study in relapsed or refractory (R/R) large B …
447 results